Cardio Diagnostics Holdings heads into its May 20 earnings release with the stock down 15% on the week, shorts unwinding fast, and borrow costs running at nearly triple digits — a confusing mix of signals for a stock with a market cap below $5 million.
The most striking development this week is how rapidly short sellers have pulled back. Short interest has fallen 24% in just five sessions to roughly 1.7% of float — and came in at 1.1% as of the latest ORTEX read. That is not a crowded short by any measure. At the same time, borrow costs are extraordinary: the cost to borrow is running at 93% annualised, down sharply from above 230% in late March and early April but still near the top of any peer comparison. The disconnect — low actual short interest, very high borrow cost — points to a thin lending market where even minimal demand drives up rates, not to aggressive institutional shorting. Availability is 4,085% of short interest, which means there are vastly more shares available to lend than are currently borrowed; the high cost reflects the structural illiquidity of the name, not genuine squeeze pressure.
The ORTEX short score has drifted lower this week, easing to 42.2 from a recent peak above 46 at the start of May. That trajectory — shorts covering into weakness — is the positioning story here. The stock is down 19% over the past month, yet short sellers are not adding. The days-to-cover ranks in the 99th percentile, reflecting how thin daily trading volume is, but with utilisation sitting at just 2.6% against a 52-week high of 100%, there is no squeeze dynamic at play.
The price action is doing the heavy lifting. The stock closed at $1.55 on Friday, off 8% on the day and 15% on the week. Closest peer LRMR fell a similar 10% on the week, and PMVP dropped 9%, suggesting broad pressure across small-cap biotech rather than anything company-specific driving the decline. CGEM and PMN bucked the trend, each closing the week up 5-8%.
The earnings history adds context worth watching. The last four events show a heavy negative skew: the most recent print in March triggered a 47% single-day drop and a 50% five-day decline. The prior event in November 2025 brought a one-day fall of 11% and a five-day loss of 33%. The one exception was November 2025's earlier event, which produced a 28% one-day gain. With the next earnings scheduled for May 20, that pattern — three losses of 9-50% against one sharp bounce — frames the risk into next week's print.
The institutional ownership picture is thin, as expected for a sub-$5 million market cap. Jane Street is the largest disclosed holder at 2.7%, having entered a new position as of March 31. BlackRock and Vanguard hold just over 1% and 0.8% respectively, almost certainly through passive index exposure. Insider data is stale — the most recent disclosed trades date to September 2024 — so there is no current read on management's own positioning.
The setup heading into May 20 is therefore a falling stock, retreating shorts, expensive borrow relative to the actual short base, and an earnings history that skews sharply negative. What to watch is whether the borrow cost continues its descent from the March-April highs — if it drops toward more normal levels ahead of the print, that would confirm shorts have largely moved on, and the next move is driven entirely by the earnings release itself.
See the live data behind this article on ORTEX.
Open CDIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
